Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1952)	10/13/2008 2:14:45 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

NTII is up 63.54% with volume still below its ADV.<g> It announced today an agreement with the FDA to consolidate Viprinex PIII, which will accelerate the time to 'Pivotal Data'.<g> bigcharts.marketwatch.com The stock still needs to get back to the $1 level.<g> It is trading around 0.6xBV with negligible LTD, but with negative CF around $0.45 <g> In March it announced an agreement with the Buck Institute, that granted NTII worldwide license relating to a protein that has been shown in animal studies, to reverse the symptoms of AD.<g> NTII agreed to fund a research program at the BI relating to developing this protein for up to 3 Yrs.Funding for the initial year will total $1,200,000 Bernard